Guillaume Favier


Guillaume is a research scientist and has worked both in academia and industry, focusing on the synthesis of new molecules for the treatment of chronic diseases. He now works as a Director within KPMG’s Healthcare and Life Sciences strategy practice, leading on international Quality of Care programmes.

His projects focus on the identification and dissemination of good practice in the management of patients across care settings and geographies with the ultimate goal of improving outcomes.  

As a trustee of Cardiomyopathy UK, Guillaume hopes to apply his strategy skill-set to support the cardiomyopathy community.